3 documents

Read All
07:00 , Jun 2, 2014 |  BioCentury  |  Emerging Company Profile

Panoptes: Dual attack in uveitis

Panoptes Pharma GmbH 's selective dihydroorotate dehydrogenase inhibitor PP-001 could provide better efficacy and safety than standard corticosteroid therapy in autoimmune uveitis, where a new therapy hasn't been approved in decades. PP-001's dual mechanism and...
Read More
07:00 , Sep 30, 2013 |  BC Week In Review  |  Financial News

Panoptes Pharma completes venture financing

Panoptes Pharma GmbH , Vienna, Austria   Business: Ophthalmic   Date completed: 9/26/13   Type: Venture financing   Raised: €1.2 million ($1.6 million)   Investors: aws-Life Science Austria; private investors  ...
Read More
02:15 , Sep 27, 2013 |  BC Extra  |  Financial News

Panoptes closes EUR1.2M seed round, in-licenses 4SC compound

Panoptes Pharma GmbH (Vienna, Austria) raised EUR 1.2 million ($1.6 million) in a seed round from AWS-Life Science Austria and private investors and received rights to preclinical chronic uveitis and conjunctivitis compound PP-001 from 4SC...
Read More